Back to Search
Start Over
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
- Source :
-
The oncologist [Oncologist] 2024 Jun 03; Vol. 29 (6), pp. e741-e749. - Publication Year :
- 2024
-
Abstract
- Background: Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment.<br />Patients and Methods: This multicenter, retrospective, observational study, conducted across 4 medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio.<br />Results: The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival period was 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% CI, 0.70-2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61-2.47). Consistent results were obtained for subgroups receiving palbociclib (nā =ā 177) and abemaciclib (nā =ā 63) without propensity score matching. Adverse event incidence and severity were similar in both groups.<br />Conclusion: The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted.<br /> (© The Author(s) 2024. Published by Oxford University Press.)
- Subjects :
- Humans
Female
Retrospective Studies
Aged
Middle Aged
Piperazines therapeutic use
Piperazines adverse effects
Piperazines pharmacology
Piperazines administration & dosage
Aminopyridines therapeutic use
Aminopyridines pharmacology
Aminopyridines adverse effects
Protein Kinase Inhibitors therapeutic use
Protein Kinase Inhibitors adverse effects
Protein Kinase Inhibitors pharmacology
Pyridines therapeutic use
Pyridines pharmacology
Pyridines adverse effects
Pyridines administration & dosage
Benzimidazoles therapeutic use
Benzimidazoles pharmacology
Benzimidazoles adverse effects
Adult
Aged, 80 and over
Breast Neoplasms drug therapy
Breast Neoplasms mortality
Breast Neoplasms pathology
Proton Pump Inhibitors therapeutic use
Proton Pump Inhibitors pharmacology
Proton Pump Inhibitors adverse effects
Proton Pump Inhibitors administration & dosage
Cyclin-Dependent Kinase 6 antagonists & inhibitors
Cyclin-Dependent Kinase 4 antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1549-490X
- Volume :
- 29
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- The oncologist
- Publication Type :
- Academic Journal
- Accession number :
- 38340010
- Full Text :
- https://doi.org/10.1093/oncolo/oyae015